Despite their significant impact on human and sustainable development, relatively few new health technologies are available for tuberculosis (TB), malaria and neglected tropical diseases (NTDs). Most current treatments and diagnostic tests for these diseases are outdated and ineffective.

Innovation is essential, but insufficient for health systems to deliver new health technologies to the communities that need them most. With few new health technologies approved for TB, malaria and NTDs, addressing the factors that impede their effective access and delivery is all the more crucial.

In many low- and middle-income countries (LMICs), the delivery of accessible, affordable and optimal health technologies to large segments of their population remains a major problem, which represents a significant barrier to achieving universal health coverage (UHC).

The 2030 Agenda for Sustainable Development recognizes the tremendous impact of diseases such as TB, malaria and NTDs have on human development. Hence, Sustainable Development Goal (SDG) 3, on health and well-being, has set an ambitious target to end these epidemics by 2030. Towards this end, the SDGs underline the need for more research and development (R&D) on new medicines and vaccines, as well as for UHC and health systems strengthening to enable access to essential health technologies.

The Access and Delivery Partnership (ADP) helps LMICs reach health-related targets of the SDGs by strengthening domestic systems and processes that are needed to access and deliver new health technologies for TB, malaria and NTDs. Hence, the ADP focuses on strengthening capacities within the essential cross-sectoral “pathways” contributing to effective access and delivery: an enabling policy and legal framework, implementation research, safety monitoring, priority setting, and supply chain management.

During this Side Event, the ADP brings together a group of experts from various disciplines to discuss how greater linkages can and should be made between health R&D and innovation, and the effective access and delivery of new health technologies. Not only are marginalized populations in LMICs disproportionately burdened by TB, malaria and NTDs, they are also often excluded from access to appropriate diagnosis and treatment. Promoting the innovation, access and delivery of health technologies is vital towards ensuring equitable health outcomes among vulnerable communities.

For more information about this side event, please contact Cecilia Oh (cecilia.oh@undp.org) or Les Ong (leslie.ong@undp.org).
AGENDA

14:00–14:15  Opening/Welcome
Mandeep Dhaliwal, Director, HIV, Health and Development Team, UNDP
Eiji Hinoshita, Director, Global Health Policy Division, International Cooperation Bureau, Ministry of Foreign Affairs of Japan

14:15–15:00  Panel Discussion 1 – Health R&D and innovation: Ensuring a needs-driven approach
This panel discusses the means by which health R&D and product development can meet the needs of vulnerable populations, and be appropriate to the level of capacities of communities and countries in resource-limited settings.

Moderator:
Amie Batson, Chief Strategy Officer and Vice President of Strategy and Learning, PATH

Panel:
Hayato Urabe, Director, Investment Strategy and Management, Global Health Innovative Technology (GHIT) Fund
Jean-Michel Piedagnel, Head, South-East Asia Regional Office, Drugs for Neglected Diseases Initiative (DNDi)
Solomon Nwaka, Executive Director, African Network for Drugs and Diagnostics Innovation (ANDi)

15:00–15:30  Coffee break

15:30–16:30  Panel Discussion 2 – Access to health technologies: How do we reach people in need?
This panel focuses on the processes of access, introduction and scale-up of new medicines, vaccines and diagnostic tools in LMICs. What are the key factors that can promote or impede the effective access and introduction of new health technologies in LMICs?

Moderator:
Garry Aslanyan, Manager, Partnerships and Governance, Special Programme for Research and Training in Tropical Diseases (TDR), WHO

Panel:
Eiji Hinoshita, Director, Global Health Policy Division, International Cooperation Bureau, Ministry of Foreign Affairs of Japan
Kriang Tangsanga, Chair, Committee for the National Essential Drugs List, Thailand
Mandeep Dhaliwal, Director, HIV, Health and Development Team, UNDP
Yodi Mahendradhata, Director, Centre for Health Policy and Management, Universitas Gadjah Mada, Indonesia

16:30–16:45  Close

16:45–19:00  Cocktail Reception

About ADP
The Access and Deliver Partnership (ADP) assists low- and middle-income countries in strengthening domestic systems and processes to access and deliver new health technologies for TB, malaria and NTDs. With support from the Government of Japan, the ADP is led by UNDP, in collaboration with WHO/TDR and PATH.

For more information about the Partnership:
www.adphealth.org
@ADP_health